CG Oncology Initiates PIVOT-006 Phase 3 Trial for Cretostimogene Targeting Intermediate-risk Non-Muscle Invasive Bladder Cancer

CG Oncology Initiates PIVOT-006 Phase 3 Trial for Cretostimogene Targeting Intermediate-risk NMIBC Overview Company: CG Oncology, Inc. Indication: Intermediate-risk Non-Muscle Invasive Bladder Cancer (NMIBC) Drug: Cretostimogene Trial Phase: Phase 3 NCT ID: NCT06111235 Trial Details On February 27, 2024, CG Oncology announced the commencement of their Phase 3 PIVOT-006 clinical trial. This pivot..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 28.
  • textsms

CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study with Cretostimogene Grenadenorepvec in BCG-Unresponsive High-Risk NMIBC

CG Oncology Inc. has successfully completed the enrollment of patients in their BOND-003 Phase 3 monotherapy study. This study aims to evaluate the effectiveness of cretostimogene grenadenorepvec as a potential treatment for high-risk non-muscle invasive bladder cancer (NMIBC) patients who do not respond to Bacillus Calmette-Guerin (BCG). The BOND-003 study has enrolled a total of 110 patients w..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 24.
  • textsms